Draft R&D Tax Incentive Determination on clinical trials

Draft R&D Tax Incentive Determination on clinical trials (Phase 0-III) for an unapproved therapeutic good

The Council welcomed changes to the R&D tax incentive announced in the 2020-21federal budget that would effectively give the Board of Industry Innovation and Science Australia the ability to provide determinations in order to engender greater clarity and certainty on eligible R&D activities for specific circumstances over and above existing guidance material.

The Draft R&D Tax Incentive Determination on clinical trials (Phase 0-III) for an unapproved therapeutic good is a very positive step in the right direction in providing more certainty on the definition of core R&D activities for businesses conducting clinical trials Phase 0-III.

View full submission

TO EMPOWER THE PRIVATE CAPITAL
INDUSTRY TO BUILD BETTER BUSINESSES

Head Office
Level 12, Aurora Place
88 Phillip Street
Sydney NSW 2000

Telephone
+61 2 8243 7000
—
Email Enquiry

Protect yourself from scams: the Australian Investment Council advises its members to be aware of text messages, phone calls, emails and other unsolicited contact that use the Australian Investment Council brand without our permission. We have been made aware of unrelated third parties seeking to sell the Australian Investment Council member list. The Australian Investment Council does not request payment for our member list.

Please report online scams and fraudulent activity to the Australian Taxation Office on 1300 795 995 or Scamwatch via their website.

Picture Logo
There are no records.